1. Home
  2. SABS vs CREX Comparison

SABS vs CREX Comparison

Compare SABS & CREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABS
  • CREX
  • Stock Information
  • Founded
  • SABS 2014
  • CREX N/A
  • Country
  • SABS United States
  • CREX United States
  • Employees
  • SABS N/A
  • CREX N/A
  • Industry
  • SABS Biotechnology: Pharmaceutical Preparations
  • CREX EDP Services
  • Sector
  • SABS Health Care
  • CREX Technology
  • Exchange
  • SABS Nasdaq
  • CREX Nasdaq
  • Market Cap
  • SABS 15.8M
  • CREX 16.8M
  • IPO Year
  • SABS N/A
  • CREX N/A
  • Fundamental
  • Price
  • SABS $1.85
  • CREX $2.11
  • Analyst Decision
  • SABS Strong Buy
  • CREX Strong Buy
  • Analyst Count
  • SABS 6
  • CREX 2
  • Target Price
  • SABS $11.17
  • CREX $8.00
  • AVG Volume (30 Days)
  • SABS 58.6K
  • CREX 48.1K
  • Earning Date
  • SABS 05-27-2025
  • CREX 05-14-2025
  • Dividend Yield
  • SABS N/A
  • CREX N/A
  • EPS Growth
  • SABS N/A
  • CREX N/A
  • EPS
  • SABS N/A
  • CREX N/A
  • Revenue
  • SABS $377,835.00
  • CREX $48,303,000.00
  • Revenue This Year
  • SABS N/A
  • CREX $10.05
  • Revenue Next Year
  • SABS $50.00
  • CREX $18.73
  • P/E Ratio
  • SABS N/A
  • CREX N/A
  • Revenue Growth
  • SABS N/A
  • CREX 1.68
  • 52 Week Low
  • SABS $1.00
  • CREX $1.28
  • 52 Week High
  • SABS $5.01
  • CREX $5.20
  • Technical
  • Relative Strength Index (RSI)
  • SABS 58.32
  • CREX 65.56
  • Support Level
  • SABS $1.76
  • CREX $1.62
  • Resistance Level
  • SABS $2.15
  • CREX $2.23
  • Average True Range (ATR)
  • SABS 0.19
  • CREX 0.14
  • MACD
  • SABS 0.02
  • CREX 0.05
  • Stochastic Oscillator
  • SABS 51.61
  • CREX 80.95

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

About CREX Creative Realities Inc.

Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.

Share on Social Networks: